Britannia Life Sciences Inc.
BLAB
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 81.20K | 122.70K | -- | 1.24M | 172.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 81.20K | 122.70K | -- | 1.24M | 172.00K |
| Cost of Revenue | 53.20K | 102.30K | -- | 518.20K | 57.50K |
| Gross Profit | 28.00K | 20.50K | -- | 723.40K | 114.50K |
| SG&A Expenses | 523.10K | 271.10K | -- | 845.60K | 254.20K |
| Depreciation & Amortization | 11.50K | 11.30K | -- | -- | 11.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 587.90K | 384.60K | -- | 1.36M | 322.70K |
| Operating Income | -506.60K | -261.90K | -- | -122.20K | -150.70K |
| Income Before Tax | -298.60K | -499.40K | -- | -24.10K | -1.05M |
| Income Tax Expenses | -- | -- | -- | 43.60K | -- |
| Earnings from Continuing Operations | -298.60K | -499.40K | -- | -67.70K | -1.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 256.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -30.10K | -82.30K |
| Net Income | -298.60K | -499.40K | -- | -97.80K | -875.80K |
| EBIT | -506.60K | -261.90K | -- | -122.20K | -150.70K |
| EBITDA | -495.20K | -250.60K | -- | -102.90K | -139.70K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.01 | -- | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.01 | -- | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Average Diluted Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |